Beta Bionics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBNX research report →
Companywww.betabionics.com
Beta Bionics, Inc. , a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
- CEO
- Sean T. Saint
- IPO
- 2025
- Employees
- 352
- HQ
- Irvine, CA, US
Price Chart
Valuation
- Market Cap
- $450.52M
- P/E
- -6.76
- P/S
- 4.09
- P/B
- 1.66
- EV/EBITDA
- -6.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 57.15%
- Op Margin
- -70.13%
- Net Margin
- -60.27%
- ROE
- -23.00%
- ROIC
- -27.31%
Growth & Income
- Revenue
- $100.25M · 53.94%
- Net Income
- $-73,200,000 · -33.68%
- EPS
- $-1.81 · 78.95%
- Op Income
- $-71,681,000
- FCF YoY
- -8.81%
Performance & Tape
- 52W High
- $32.71
- 52W Low
- $8.80
- 50D MA
- $10.58
- 200D MA
- $18.84
- Beta
- 3.28
- Avg Volume
- 1.03M
Get TickerSpark's AI analysis on BBNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 25 | Hopman Mark | sell | 856 |
| Dec 4, 25 | Hopman Mark | sell | 2,061 |
| Dec 2, 25 | Russell Steven Jon | sell | 1,025 |
| Feb 27, 26 | Mensinger Mike | other | 91,520 |
| Feb 27, 26 | Russell Steven Jon | other | 91,520 |
| Feb 27, 26 | Saint Sean | other | 287,944 |
| Feb 27, 26 | Hopman Mark | other | 91,520 |
| Feb 27, 26 | Feider Stephen | other | 110,342 |
| Mar 4, 26 | Hopman Mark | sell | 353 |
| Feb 27, 26 | Hopman Mark | other | 109,105 |
Our BBNX Coverage
We haven't published any research on BBNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BBNX Report →